Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2-year Open-label Extension Study of Lebrikizumab in Moderate-to-Severe Atopic Dermatitis
2022-502575-30-00Phase 3Completed
- Sponsor
- Almirall
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of lebrikizumab in atopic dermatitis (AD), sponsored by Almirall. Primary endpoint: Proportion of patients discontinued from study treatment due to treatment-emergent adverse events. Started May 2023; status: completed.
02
Drugs
lebrikizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2022-502575-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502575-30-00.